Treatment patterns and healthcare resource utilization in patients with metastatic hormone-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer in China: a real-world observational study-Reference-Cited by-同舟云学术

Treatment patterns and healthcare resource utilization in patients with metastatic hormone-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer in China: a real-world observational study

Published:2024-03-11 Issue:1 Volume:27 Page:361-369
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Wang Yong¹,Liu Chunxiao²,Liu Chuan³,Lu Yongji⁴,Ban Lu⁵,Niu Yuanjie¹^ORCID

Affiliation:

1. Department of Urology, Second Hospital of Tianjin Medical University, Tianjin, China

2. Department of Urology, Zhujiang Hospital of Southern Medical University, Guangzhou City, China

3. Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

4. Health Economics and Outcomes Research, Astellas Pharma, Shanghai, China

5. Evidera, PPD, Beijing, China

Funder

Astellas Pharma Inc.

Pfizer

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2024.2320001

Reference32 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer—A Systematic Literature Review with Application to the Canadian Context

3. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I

4. Thapa B Mahendraker N Ramphul K. Paraneoplastic syndromes. In: StatPearls (internet). Treasure Island (FL): StatPearls Publishing; 2023. [cited 2023 Aug 30]. https://www.ncbi.nlm.nih.gov/books/NBK507890/

5. Burden of Prostate Cancer in China, 1990–2019: Findings From the 2019 Global Burden of Disease Study